3 Sales Growth Stocks to Bet on as Markets Remain Resilient

The article screens for stocks with strong historical sales growth, cash flow above $500 million, favorable valuation and estimate-revision metrics, and a Zacks Rank of 2 or better. It highlights CACI International with expected fiscal 2027 sales growth of 10.6%, Globe Life with 2026 sales growth of 6.3%, and Knight-Swift Transportation with 2026 sales growth of 7.1%, all carrying Zacks Rank #2. The piece is broadly constructive on these names but is mainly a stock-selection commentary rather than a company-specific catalyst.

Analysis

The market is rewarding companies where revenue visibility is more durable than macro sentiment, which is why this screen matters more for relative performance than for absolute direction. CACI is the cleanest expression of that thesis: defense/IC spending is one of the few end-markets where budget inertia can offset a weakening private-cycle backdrop, and that typically shows up first in order flow rather than headlines. GL is more interesting as a defensive compounder than a growth name — if rates stay elevated, its spread income supports earnings, but if the curve abruptly bull-steepens, the market may rotate away from the whole insurance complex even if sales remain intact.

KNX is the most cyclically levered of the three, so its upside depends on freight pricing inflecting before the broader industrial slowdown becomes visible in volumes. That creates a second-order setup: if management commentary is even modestly constructive on yield discipline or cost controls, the stock can re-rate faster than spot freight data because investors will look through near-term volume weakness to margin normalization. Conversely, if diesel and labor costs re-accelerate, KNX has the least insulation despite decent top-line growth.

The common denominator is that the screen is biased toward names with cash and revision momentum, but the real catalyst is not sales growth itself — it is whether the next two earnings cycles confirm that growth is translating into operating leverage. The market is likely underpricing how quickly estimate revisions can compound in these names if guidance stays stable. The main risk is that this becomes a crowded 'quality growth at a reasonable price' factor trade, which would make the group vulnerable to a macro shock or a broad reversal in small-cap/industrial sentiment.

Key Decisions for Investors

• Go long CACI on any post-earnings or macro-driven pullback over the next 2-6 weeks; target a 10-15% upside re-rate if order visibility and backlog conversion remain intact, with downside limited by government-spend insulation.
• Use GL as a defensive pair leg: long GL / short a lower-quality life insurer or broad financials basket for 1-3 months; the thesis is stability of cash generation and less earnings dispersion if rates stay volatile.
• Take a tactical long KNX only on confirmation that freight pricing is stabilizing; horizon 1-2 quarters, with a better risk/reward if entered after a weak tape because the stock can snap back on any margin-guidance improvement.
• If the group rallies without estimate revisions accelerating, fade the move via a basket short against the three names; this is a factor-driven setup where valuation can outrun fundamentals over 4-8 weeks.
• Favor a long CACI / short KNX pair for the next 1-2 quarters as a cleaner defensive-vs-cyclical relative-value expression, with CACI’s cash-backed visibility offsetting KNX’s exposure to a late-cycle freight slowdown.